Controversies in the treatment of Crohn's disease: The case for an accelerated step-up treatment approach

World Journal of Gastroenterology

Volumn 14, Issue 17, 2008, Pages 2670-2677

  Shergill, Amandeep K ^a   Terdiman, Jonathan P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti tumor necrosis factor antibodies; Crohn's disease; Immunomodulators; Mucosal healing; Step up; Top down

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; HYDROCORTISONE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PLACEBO; PREDNISONE; STEROID; TUMOR NECROSIS FACTOR ANTIBODY; ANTIINFLAMMATORY AGENT; BIOLOGICAL FACTOR; GASTROINTESTINAL AGENT; IMMUNOLOGIC FACTOR;

CANCER RISK; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DISEASE CONTROL; DISEASE RESISTANCE; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL SURGERY; HEALING; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; MONOTHERAPY; REMISSION; REVIEW; SINGLE DRUG DOSE; SYMPTOM; UNSPECIFIED SIDE EFFECT; DISEASE COURSE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; INTESTINE MUCOSA; PATHOPHYSIOLOGY; PATIENT SELECTION; RISK ASSESSMENT; TREATMENT OUTCOME; WOUND HEALING;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL FACTORS; CROHN DISEASE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; INTESTINAL MUCOSA; PATIENT SELECTION; RISK ASSESSMENT; STEROIDS; TREATMENT OUTCOME; WOUND HEALING;

EID: 49649101871     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.2670     Document Type: Review

References (49)

1. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004; 2: 379-388
2. Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, Singleton JW. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77: 847-869
3. Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, Mayer L, Regueiro C, Rutgeerts P, Sandborn WJ, Sands BE, Schreiber S, Targan S, Travis S, Vermeire S. American gastroenterological association consensus development conference on the use of biologies in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007; 133: 312-339
4. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 940-987
5. Hanauer SB. Clinical perspectives in Crohn's disease. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down". Rev Gastroenterol Disord 2007; 7 Suppl 2: S17-S22
6. Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007; 56: 453-455
7. Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1017-1024; quiz 976
8. Vermeire S, van Assche G, Rutgeerts P. Review article: Altering the natural history of Crohn's disease - evidence for and against current therapies. Aliment Pharmacol Ther 2007; 25: 3-12
9. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995; 30: 699-706
10. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-260
11. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-250
12. Munkholm P, Langholz E, Davidsen M, Binder V. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993; 105: 1716-1723
13. Binder V, Hendriksen C, Kreiner S. Prognosis in Crohn's disease-based on results from a regional patient group from the county of Copenhagen. Gut 1985; 26: 146-150
14. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-630
15. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99: 956-963
16. Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63: 433-464
17. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-413
18. Froslie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-422
19. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, Jesdinsky H. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249-266
20. Sandborn WJ, Feagan BG, Lichtenstein GR. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther 2007; 26: 987-1003
21. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994; 331: 836-841
22. Sandborn WJ, Lofberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind placebo-controlled trials. Am J Gastroenterol 2005; 100: 1780-1787
23. Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A, D'Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel JF, Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55 Suppl 1: i16-i35
24. Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, Rene E. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990; 98: 811-818
25. Agrawal A, Durrani S, Leiper K, Ellis A, Morris AI, Rhodes JM. Effect of systemic corticosteroid therapy on risk for intra-abdominal or pelvic abscess in non-operated Crohn's disease. Clin Gastroenterol Hepatol 2005; 3: 1215-1220
26. Baunigart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641-1657
27. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37: 674-678
28. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999; 50: 667-671
29. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 237-241
30. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895-902
31. Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24: 715-729
32. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54: 1121-1125
33. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. Pediatr Gastroenterol Nutr 2007; 44: 265-267
34. Inadomi JM, Terdiman J. Exploring utilities and outcomes with infliximab therapy. Clin Gastroenterol Hepatol 2006; 4: 976-978
35. Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000; 95: 3189-3194
36. Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132: 863-873; quiz 1165-1166
37. Sandborn WJ, Colombel JF, Panes J, Scholmerich J, McColm J, Schreiber S. Higher remission and maintenance of response rates with subcutaneous monthly Certolizumab Pegol in patients with recent-onset Crohn's Disease: Data from PRECISE 2. Am J Gastroenterol 2006; 101 Suppl 2: S394
38. Schreiber S, Reinisch W, Colombel JF, Sandborn WJ, Hommes DW, Li J, Kent JD, Pollack PF. Early Crohn's Disease shows high levels Of remission to therapy with Adalimumab: Sub-analysis of Charm. Gastroenterology 2007; 132: A-147
39. D'Haens G, Hommes DW, Baert F, De Vos M, Caenepeel F, Van Assche G, Lambrecht G, Coche JC, Vermeire S, Van Camp M. A combined regimine of Infliximab and Azathioprine induces better endoscopic mucosal healing than classic step-up therapy in newly diagnosed Crohn's Disease. Gastroenterology 2006; 130: A-110
40. Hommes DW, Baert F, Van Assche G, Caenepeel F, Vergauwe P, Tuynman H, De Vos M, Van Deventer S, Stitt L, Rutgeerts P, Feagan BC, D'Haens G. The ideal management of Crohn's Disease: Top Down versus Step Up Strategies, a randomized controlled trial. Gastroenterology 2006; 130: A-108
41. Lowenberg M, Peppelenbosch M, Hommes D. Biological therapy in the management of recent-onset Crohn's disease: why, when and how? Drugs 2006; 66: 1431-1439
42. Lemann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, Laharie D, Moreau J, Cadiot G, Picon L, Bourreille A, Sobahni I, Colombel JF. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006; 130: 1054-1061
43. Van Assche G, Paintaud G, Magdelaine C, D'Haens G, Baert F, Vermeire S, Noman M, Temant D, Watier H, Rutgeerts P. Concomitant immunosuppression does not impact on the outcome of maintenance Infliximab therapy in Crohn's Disease: Final results of the IMID trial. Gastroenterology 2007; 132: A-103
44. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65
45. Lichtenstein GR, Diamond RH, Wagner C, Olson A, Hegedus R, Bala M, Sandborn WJ. Infliximab administered as 3-dose induction followed by scheduled maintenance therapy in IBD: comparable clinical outcomes with or without concomitant immunomodulators, Gastroenterology 2007; 132: A-146
46. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006; 130: 650-656
47. Sands BE, Arsenault JE, Rosen MJ, Alsahli M, Bailen L, Banks P, Bensen S, Bousvaros A, Cave D, Cooley JS, Cooper HL, Edwards ST, Farrell RJ, Griffin MJ, Hay DW, John A, Lidofsky S, Olans LB, Peppercom MA, Rothstein RI, Roy MA, Saletta MJ, Shah SA, Warner AS, Wolf JL, Vecchio J, Winter HS, Zawacki JK. Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol 2003; 98: 2712-2718
48. Dubinsky MC, Lin YC, Dutridge D, Picornell Y, Landers CJ, Farrior S, Wrobel I, Quiros A, Vasiliauskas EA, Grill B, Israel D, Bahar R, Christie D, Wahbeh G, Silber G, Dallazadeh S, Shah P, Thomas D, Kelts D, Hershberg RM, Elson CO, Targan SR, Taylor KD, Rotter JI, Yang H. Serum immune responses predict rapid disease progression among children with Crohn' s disease: immune responses predict disease progression. Am J Gastroenterol 2006; 101: 360-367
49. Vermeire S. Review article: genetic susceptibility and application of genetic testing in clinical management of inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24 Suppl 3: 2-10